Silyl-heparin adsorption improves the in vivo thromboresistance of carbon-coated polytetrafluoroethylene vascular grafts

Laredo, James; Li, Xue; Husak, Vicki; Ellinger, Joan; Greisler, Howard P.

doi:10.1016/j.amjsurg.2003.07.015

Cited by 24 publications

(14 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To address this problem, many approaches have been investigated to recreate the anti-thrombogenic characteristics of the vasculature. Some researchers have relied on the immobilization of anticoagulant or antiproliferative components within the lumen of the graft [30][31][32][33][34][35]. Nonetheless, it is generally accepted that the most promising approach to long-term success of a prosthetic graft would likely involve the creation of an intact functional endothelium in the lumen of the graft [36,37].…”

Section: Discussionmentioning

confidence: 99%

Toward Engineering a Human Neoendothelium with Circulating Progenitor Cells

et al. 2009

View full text Add to dashboard Cite

Tissue-engineered vascular grafts may one day provide a solution to many of the limitations associated with using synthetic vascular grafts. However, identifying a suitable cell source and polymer scaffold to recreate the properties of a native blood vessel remains a challenge. In this work, we assess the feasibility of using endothelial progenitor cells (EPCs) found in circulating blood to generate a functional endothelium on poly(1,8-octanediol-co-citrate) (POC), a biodegradable elastomeric polyester. EPCs were isolated from human blood and biochemically differentiated into endothelial-like cells (HE-like) in vitro. The differentiated cell phenotype and function was confirmed by the appearance of the characteristic endothelial cell (EC) cobblestone morphology and positive staining for EC markers, von Willebrand factor, vascular endothelial cadherin, flk-1, and CD31. In addition, HE-like cells cultured on POC express endothelial nitric oxide synthase at levels comparable to aortic ECs. Furthermore, as with mature endothelial cells, HE-like cell populations show negligible expression of tissue factor. Similarly, HE-like cells produce and secrete prostacyclin and tissue plasminogen activator at levels comparable to venous and aortic ECs. When compared to fibroblast cells, HE-like cells cultured on POC show a decrease in the rate of plasma and wholeblood clot formation as well as a decrease in platelet adhesion. Finally, the data show that HE-like cells can withstand physiological shear stress of 10 dynes/cm 2 when cultured on POC-modified expanded poly(tetrafluoroethylene) vascular grafts. Collectively, these data are the foundation for future clinical studies in the creation of an autologous endothelial cell-seeded vascular graft. STEM CELLS 2010;28:318-328 Disclosure of potential conflicts of interest is found at the end of this article.

show abstract

Section: Discussionmentioning

confidence: 99%

Toward Engineering a Human Neoendothelium with Circulating Progenitor Cells

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Early thrombosis represents the major cause of graft occlusion. To overcome the problem, coating of the grafts with antithrombogenic materials, such as heparin, 1 ethylene oxide, 2 and endothelial cells (ECs), 3 has been applied, but the results were not satisfactory. These approaches showed the moderate improvement of vascular graft patency in animal models, but did not achieve long-term patency due to graft thrombosis.…”

Section: Introductionmentioning

confidence: 99%

Enhancement of in vivo endothelialization of tissue‐engineered vascular grafts by granulocyte colony‐stimulating factor

Cho

Lim

Chu

et al. 2005

J Biomedical Materials Res

View full text Add to dashboard Cite

Successful reconstruction of large-diameter blood vessel in humans has been demonstrated using the tissue engineering technique, but improvement in patency of small-diameter bioartificial vascular graft remains a great challenge. This study reports that granulocyte colony-stimulating factor (G-CSF) can enhance in vivo endothelialization of tissue-engineered vascular grafts, which could be used to improve patency of small-diameter vascular graft. Vascular grafts were tissue engineered with decellularized canine abdominal aortas and canine autologous bone marrow-derived cells. Prior to cell seeding onto decellularized graft matrices, bone marrow-derived cells were induced to differentiate into endothelial cells and smooth muscle cells. The cell-seeded vascular grafts were implanted into the abdominal aortas of bone marrow donor dogs. Before and after graft implantation, G-CSF was administered subcutaneously to the dogs (n = 3). The grafts implanted into the dogs not receiving G-CSF were used as controls (n = 3). Eight weeks after implantation, grafts in both groups showed regeneration of vascular tissues including endothelium and smooth muscle. Importantly, endothelium formation was more extensive in the G-CSF-treated grafts than in the control grafts, as assessed with reverse transcription polymerase chain reaction, western blot, and immunohistochemistry. In addition, intimal hyperplasia was significantly reduced in the G-CSF-treated grafts compared to the control grafts. This study suggests that G-CSF administration could be applied to improve patency of small-diameter tissue-engineered vascular grafts.

show abstract

“…Inhibition of thrombin and fibrin formation is mediated via attachment of biochemically active molecules such as heparin [2,3,44,45,46,47,48,49,50] or thrombomodulin [51,52,53]. The best-known technique is heparin-coating, which finds broad clinical acceptance in cardiopulmonary bypass circuits [2,3].…”

Section: Strategies To Prevent Protein and Platelet Adhesionmentioning

confidence: 99%

Current Strategies in Cardiovascular Biomaterial Functionalization

Schopka

Schmid

et al. 2010

Materials

View full text Add to dashboard Cite

Prevention of the coagulation cascade and platelet activation is the foremost demand for biomaterials in contact with blood. In this review we describe the underlying mechanisms of these processes and offer the current state of antithrombotic strategies. We give an overview of methods to prevent protein and platelet adhesion, as well as techniques to immobilize biochemically active molecules on biomaterial surfaces. Finally, recent strategies in biofunctionalization by endothelial cell seeding as well as their possible clinical applications are discussed.

show abstract

Silyl-heparin adsorption improves the in vivo thromboresistance of carbon-coated polytetrafluoroethylene vascular grafts

Cited by 24 publications

References 11 publications

Toward Engineering a Human Neoendothelium with Circulating Progenitor Cells

Toward Engineering a Human Neoendothelium with Circulating Progenitor Cells

Enhancement of in vivo endothelialization of tissue‐engineered vascular grafts by granulocyte colony‐stimulating factor

Current Strategies in Cardiovascular Biomaterial Functionalization

Contact Info

Product

Resources

About